National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 8) (No. PB 57 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L01631

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 57 of 2013
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 8)
 
National Health Act 1953
___________________________________________________________________________
 
I, Steve Dunlop, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Medical Research, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 19 August 2013
 
 
 
 
 
 
 
 
 
 
 
 
STEVE DUNLOP
Acting Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No.8).
 
(2)                This Instrument may also be cited as PB 57 of 2013.
 
2             Commencement
                This Instrument commences on 1 September 2013.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection:
omit:
Gemzar
LY
MP
 
D
 
 
 
[2]    Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection:
omit:
Gemzar
LY
MP
 
D
 
 
 
[3]    Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 2 g  (as hydrochloride) with manner of administration Injection with a brand of DBL Gemcitabine for Injection:
insert:
Gemcitabine Actavis
2000
 
WQ
MP
 
D
 
[4]    Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 100 mg in 16.7 mL with manner of administration Injection:
omit:
Paclitaxel Pfizer
PF
MP
C3186
C3890 
C3902
C3917
C3955
C3956
D
 
[5]    Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 30 mg in 5 mL with manner of administration Injection:
omit:
Paclitaxel Pfizer
 
PF
MP
C3186
C3890 
C3902
C3917
C3955
C3956
D
[6]    Schedule 2, entry for Granisetron in the form Concentrated injection 3 mg (as hydrochloride) in 3 mL with manner of administration Injection with a brand of Granisetron Kabi:
substitute:                                  
   
 
 
 
 
 
 

Concentrated injection 3 mg (as hydrochloride) in 3 mL
Injection
Granisteron-AFT
 
Granisetron Kabi
AE
 
PK
EMP
 
EMP
C4139
 
C4139

 
1
 
1

0

0
 

 
 
[7]    Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection:
omit:
Zofran
AS
EMP
C3050
 
1
0
 
 
[8]    Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection:
omit:
Zofran
AS
EMP
C3050
 
1
0